Abstract
141/2000 of the European Parliament and the Council of 16 December 1999 on orphan medicinal products. Official Journal of the European Union, January 22, 2000, L18. 6 Drummond M, Barbieri M, Cook J, et al. Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force Report. Value Health 2009;12: 409–18. 7 ISPOR. Pharmacoeconomic guidelines around the world. Available from: http://www.ispor.org/PEguidelines/index.asp [Accessed April 13, 2009]. 8 Manca A. Economic data transferability for HTA: are we there yet? Value Health 2009;12:407. 9 O’Sullivan A, Thompson D, Bekker D. Country-to-country adaptation of pharmacoeconomic research: methodologic challenges and potential solutions. ISPOR Connect 2009;15:6–8. 10 European Commission. Health Programme 2008–2013: Together for Health. Brussels: European Commission, 2007. Available from: http://ec.europa.eu/health/ph_programme/pgm2008-2013_ en.htm [Accessed April 14, 2009]. 11 European Network for Health Technology Assessment. About EUnetHTA. Available from: http://www.eunethta.net/ [Accessed April 14, 2009]. 12 European Network for Health Technology Assessment. HTA core model handbook. Available from: https://fio.stakes.fi/htacore/ handbook.html [Accessed April 14, 2009].
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
